Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Chronic Migraine Prophylaxis in Chinese Patients
NCT03193346Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in chronic migraine comparing BOTOX with Placebo (2 arms). Primary endpoint: Change from Baseline in the Frequency of Headache Days at 24 weeks. Planned start Jul 2017; status: withdrawn.
02
Drugs
onabotulinumtoxinA
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT03193346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193346.